^
Association details:
Biomarker:KRAS G12C
Cancer:Colorectal Cancer
Drug:Vectibix (panitumumab) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: B - Late Trials
New
Title:

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Excerpt:
The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined)....Table 2. Distribution of KRAS Mutations By Treatment Arm.
DOI:
10.1200/JCO.2007.14.7116